Literature DB >> 15937772

A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.

Jeffrey D Fuller1, Donald E Low.   

Abstract

We reviewed all of the published reports of cases of fluoroquinolone treatment failures for respiratory tract infection due to fluoroquinolone-resistant Streptococcus pneumoniae. There were 20 ciprofloxacin and levofloxacin treatment failures reported. Physicians should be aware, when treating pneumococcal respiratory tract infections in older patients with a fluoroquinolone, that clinical failures might occur, especially for patients with comorbid illnesses and a history of recent fluoroquinolone use.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15937772     DOI: 10.1086/430829

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  41 in total

1.  In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.

Authors:  Brian J Morrow; Wenping He; Karen M Amsler; Barbara D Foleno; Mark J Macielag; A Simon Lynch; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

2.  Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  Daniel E Rozen; Lesley McGee; Bruce R Levin; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

3.  Upgrading antibiotic use within a class: tradeoff between resistance and treatment success.

Authors:  Y Claire Wang; Marc Lipsitch
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-13       Impact factor: 11.205

4.  New real-time PCR assay using locked nucleic acid probes to assess prevalence of ParC mutations in fluoroquinolone-susceptible Streptococcus pneumoniae isolates from France.

Authors:  Jean-Winoc Decousser; Imen Methlouthi; Patrick Pina; Anne Collignon; Pierre Allouch
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

5.  Regulatory disincentives for developing antibiotics for common indications.

Authors:  Guy W Amsden
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

6.  Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa.

Authors:  George G Zhanel; Matthew Mayer; Nancy Laing; Heather J Adam
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

7.  Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin.

Authors:  Robyn Defife; Marc H Scheetz; Joe M Feinglass; Michael J Postelnick; Kimberly K Scarsi
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

8.  Genetic diversity of fluoroquinolone-nonsusceptible Streptococcus pneumoniae clinical isolates and the first identification of serotype 20B in China.

Authors:  Q Guo; C Zhuo; Y Xu; W Huang; C Wang; S Zhang; J Huang; F Hu; D Zhu; F Yang; M Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-10-04       Impact factor: 3.267

Review 9.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Mevalonate analogues as substrates of enzymes in the isoprenoid biosynthetic pathway of Streptococcus pneumoniae.

Authors:  Takashi Kudoh; Chan Sun Park; Scott T Lefurgy; Meihao Sun; Theodore Michels; Thomas S Leyh; Richard B Silverman
Journal:  Bioorg Med Chem       Date:  2009-12-24       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.